Effective June 10, 2019, PathGroup has introduced a new automated and semi-quantitative optical measurement system from Roche Diagnostics for the assessment of elevated triglycerides (lipemia), hemoglobin (hemolysis) and bilirubin (icterus) in human serum and plasma specimens. The new procedure will replace the historical subjective visual inspection procedure for marked elevations in these interfering substances. This new procedure will be performed on all plasma and serum specimens with conventional clinical chemistry and immunochemistry tests performed on the Roche analyzers. Please note that serum indices testing is independent from the assessment of unspun or partially spun specimens.
Click here to learn more.